Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT M CARLILE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1740575307
CMS profile
1388697
Location
SUMMERVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$57,564.92

357 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 6 of 8; records 251–300 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT M CARLILE

NPI 1740575307 · CMS profile ID 1388697

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SUMMERVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 8; records 251–300 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740575307?year=2021&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT M CARLILE, NPI 1740575307, CMS profile ID 1388697. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740575307?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ROBERT M CARLILE, NPI 1740575307, CMS profile ID 1388697. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740575307?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ROBERT M CARLILE, NPI 1740575307, CMS profile ID 1388697, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 8; records 251–300 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740575307?year=2021&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

357 matching records · $57,564.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 357 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 357.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $18.1604/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627295 CMS
Teva Pharmaceuticals USA, Inc. $19.1104/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587285 CMS
Teva Pharmaceuticals USA, Inc. $12.6404/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587223 CMS
AbbVie Inc. $4.1404/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213771 CMS
CSL Behring $24.2804/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820216119 CMS
AbbVie Inc. $1,100.0004/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213767 CMS
AbbVie Inc. $14.0604/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213769 CMS
Teva Pharmaceuticals USA, Inc. $13.6604/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587221 CMS
UPSHER-SMITH LABORATORIES LLC $20.1204/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834682987 CMS
Biogen, Inc. $15.4704/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827786269 CMS
AbbVie Inc. $825.0004/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213765 CMS
Novartis Pharmaceuticals Corporation $6.1704/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627279 CMS
Novartis Pharmaceuticals Corporation $16.3504/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627285 CMS
AbbVie Inc. $4.7904/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213763 CMS
Novartis Pharmaceuticals Corporation $22.6104/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627289 CMS
Teva Pharmaceuticals USA, Inc. $9.2704/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587219 CMS
Novartis Pharmaceuticals Corporation $4.1604/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627283 CMS
UCB, Inc. $8.1604/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807340431 CMS
Lilly USA, LLC $15.3403/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818730295 CMS
Teva Pharmaceuticals USA, Inc. $7.0503/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587217 CMS
Biohaven Pharmaceuticals, Inc. $34.9503/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852450261 CMS
Novartis Pharmaceuticals Corporation $10.7203/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627257 CMS
AbbVie Inc. $16.6503/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213759 CMS
AbbVie Inc. $825.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213761 CMS
ACADIA Pharmaceuticals Inc $24.8703/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837993427 CMS
SK Life Science, Inc. $26.7503/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826839807 CMS
SK Life Science, Inc. $114.7303/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826839867 CMS
SK Life Science, Inc. $19.0403/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826839795 CMS
AbbVie Inc. $6.7703/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213757 CMS
Novartis Pharmaceuticals Corporation $18.5003/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627281 CMS
Teva Pharmaceuticals USA, Inc. $11.0103/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587215 CMS
Biohaven Pharmaceuticals, Inc. $17.2903/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852450257 CMS
Teva Pharmaceuticals USA, Inc. $2.1903/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587213 CMS
Teva Pharmaceuticals USA, Inc. $19.8503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587211 CMS
Novartis Pharmaceuticals Corporation $6.4703/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627277 CMS
Adamas Pharmaceuticals, Inc. $14.3603/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834396121 CMS
Teva Pharmaceuticals USA, Inc. $9.2003/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587209 CMS
Novartis Pharmaceuticals Corporation $5.5603/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627275 CMS
Avanir Pharmaceuticals, Inc. $92.8003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801032813 CMS
GENZYME CORPORATION $18.2303/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843680443 CMS
GENZYME CORPORATION $1,885.0003/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843680507 CMS
Teva Pharmaceuticals USA, Inc. $7.0503/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839587207 CMS
EMD Serono, Inc. $15.7103/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849164195 CMS
Novartis Pharmaceuticals Corporation $6.0203/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812627271 CMS
UCB, Inc. $8.7903/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807335793 CMS
AbbVie Inc. $1,100.0003/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213753 CMS
AbbVie Inc. $13.6503/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794213755 CMS
Amgen Inc. $26.5003/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825735279 CMS
UCB, Inc. $7.8303/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807335781 CMS
ACADIA Pharmaceuticals Inc $24.2402/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837993423 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $40,435.50 304
PY2020 $44,736.97 298
PY2021 $57,564.92 357
PY2022 $70,447.69 419
PY2023 $36,265.02 392
PY2024 $74,712.56 371
PY2025 $103,362.24 423

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,580.49 1
PY2025 Principal investigator $896,196.66 33
PY2024 Recipient $7,308.40 3
PY2024 Principal investigator $610,642.92 32
PY2023 Recipient $168.48 1
PY2023 Principal investigator $339,401.85 17
PY2022 Principal investigator $53,346.98 5
PY2021 Principal investigator $2,223.80 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $300.00 11/20/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213742933
Principal investigator 1 Novo Nordisk AS $2,500.00 11/20/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213743597
Principal investigator 1 Novo Nordisk AS $2,000.00 11/20/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213777319
Principal investigator 1 Novo Nordisk AS $3,673.41 10/29/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213792738
Principal investigator 1 Eli Lilly and Company $1,019.58 10/27/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH LOW COUNTRY
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187888316
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,727.00 10/17/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068337
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $202.00 10/17/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068339
Principal investigator 1 Genentech, Inc. $17,600.00 10/16/2025 Non-covered Recipient Entity
Palmetto Clinical Research Low Country
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211636195
Principal investigator 1 Genentech, Inc. $21,989.00 10/15/2025 Non-covered Recipient Entity
Palmetto Clinical Research Low Country
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211636199
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,547.70 10/15/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068335
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $7,000.00 10/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068331
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,609.00 10/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068333
Principal investigator 1 Amgen Inc. $2,000.00 08/23/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246649433
Principal investigator 1 Novo Nordisk AS $2,500.00 08/18/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213847929
Principal investigator 1 Novo Nordisk AS $1,021.25 07/16/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213778368
Principal investigator 1 ABBVIE INC. $5,961.60 06/04/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202490163
Principal investigator 1 ABBVIE INC. $15,994.80 05/07/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202484161
Principal investigator 1 AstraZeneca UK Limited $17,983.60 05/07/2025 Non-covered Recipient Entity
GREAT LAKES PHARMACY
a phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult participants with episodic migraine No dispute reported 06/30/2026 1185547349
Principal investigator 1 Amgen Inc. $21,048.25 04/24/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) No dispute reported 06/30/2026 1246649426
Principal investigator 1 Novo Nordisk AS $2,367.40 04/21/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213754518
Principal investigator 1 Eli Lilly and Company $84,611.00 04/08/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH LOW COUNTRY
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187888426
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $378.00 03/19/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068111
Principal investigator 1 Novartis Pharmaceuticals Corporation $294,506.16 03/17/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190306487
Principal investigator 1 AstraZeneca UK Limited $59,484.30 03/05/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK
a phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult participants with episodic migraine No dispute reported 06/30/2026 1185547347
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $480.00 03/05/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068109
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,364.20 02/19/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067869
Principal investigator 1 Novo Nordisk AS $1,021.25 01/31/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213810280
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $12,557.10 01/29/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066873
Recipient Eli Lilly and Company $5,580.49 01/27/2025 Covered Recipient Physician A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187871425
Principal investigator 1 Eli Lilly and Company $12,443.00 01/27/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH LOW COUNTRY
EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY No dispute reported 06/30/2026 1187887492
Principal investigator 1 Novartis Pharmaceuticals Corporation $61,797.81 01/16/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190311815
Principal investigator 1 Amgen Inc. $3,434.91 01/09/2025 Non-covered Recipient Entity
PALMETTO GASTROENTEROLOGY CLINICAL RESEARCH, LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246646290
Principal investigator 1 Novartis Pharmaceuticals Corporation $215,155.95 01/07/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190306485
Principal investigator 1 Amgen Inc. $16,918.39 01/02/2025 Non-covered Recipient Entity
PALMETTO GASTROENTEROLOGY CLINICAL RESEARCH, LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) No dispute reported 06/30/2026 1246646286